Exhibit 10.51
T2 BIOSYSTEMS, INC.
INDUCEMENT AWARD PLAN
(as amended and restated effective February 16, 2023)
PURPOSE
The purpose of the T2 Biosystems, Inc. Inducement Award Plan (as it may be amended or restated from time to time, the “Plan”) is to promote the success and enhance the value of T2 Biosystems, Inc. (the “Company”) by linking the individual interests of eligible individuals to those of Company stockholders and by providing such individuals with an incentive for outstanding performance to generate superior returns to Company stockholders. The Plan is further intended to provide flexibility to the Company in its ability to motivate, attract, and retain the services of persons who are expected to make important contributions to the Company whose judgment, interest, and special effort the successful conduct of the Company’s operation will be largely dependent. This Plan constitutes an amendment and restatement of the T2 Biosystems, Inc. Inducement Award Plan.
DEFINITIONS AND CONSTRUCTION
Wherever the following terms are used in the Plan they shall have the meanings specified below, unless the context clearly indicates otherwise. The singular pronoun shall include the plural where the context so indicates.
|US-DOCS\105934707.2||
2
|US-DOCS\105934707.2||
In addition, if a Change in Control constitutes a payment event with respect to any portion of an Award that provides for the deferral of compensation and is subject to Section 409A of the Code, the transaction or event described in subsection (a), (b), (c) or (d) with respect to such Award (or portion thereof) must also constitute a “change in control event,” as defined in Treasury Regulation Section 1.409A-3(i)(5) to the extent required by Section 409A.
The Committee shall have full and final authority, which shall be exercised in its discretion, to determine conclusively whether a Change in Control of the Company has occurred pursuant to the above definition, and the date of the occurrence of such Change in Control and any incidental matters relating thereto; provided that any exercise of authority in conjunction with a determination of whether a Change in Control is a “change in control event” as defined in Treasury Regulation Section 1.409A-3(i)(5) shall be consistent with such regulation.
3
|US-DOCS\105934707.2||
4
|US-DOCS\105934707.2||
5
|US-DOCS\105934707.2||
6
|US-DOCS\105934707.2||
7
|US-DOCS\105934707.2||
The Administrator, in its discretion, shall determine the effect of all matters and questions relating to any Termination of Service, including, without limitation, the question of whether a Termination of Service resulted from a discharge for cause and all questions of whether particular leaves of absence constitute a Termination of Service. For purposes of the Plan, a Holder’s employee-employer relationship or consultancy relations shall be deemed to be terminated in the event that the Subsidiary employing or contracting with such Holder ceases to remain a Subsidiary following any merger, sale of stock or other corporate transaction or event (including, without limitation, a spin-off).
SHARES SUBJECT TO THE PLAN
GRANTING OF AWARDs
8
|US-DOCS\105934707.2||
OPTIONS
9
|US-DOCS\105934707.2||
10
|US-DOCS\105934707.2||
RESTRICTED STOCK
11
|US-DOCS\105934707.2||
restricted stock units
12
|US-DOCS\105934707.2||
PERFORMANCE AWARDS, DIVIDEND EQUIVALENTS, STOCK PAYMENTS
13
|US-DOCS\105934707.2||
STOCK APPRECIATION RIGHTS
14
|US-DOCS\105934707.2||
15
|US-DOCS\105934707.2||
ADditional terms of awards
16
|US-DOCS\105934707.2||
17
|US-DOCS\105934707.2||
18
|US-DOCS\105934707.2||
19
|US-DOCS\105934707.2||
ADMINISTRATION
20
|US-DOCS\105934707.2||
21
|US-DOCS\105934707.2||
MISCELLANEOUS PROVISIONS
22
|US-DOCS\105934707.2||
23
|US-DOCS\105934707.2||
24
|US-DOCS\105934707.2||
25
|US-DOCS\105934707.2||
26
|US-DOCS\105934707.2||
* * * * *
27
|US-DOCS\105934707.2||
T2 BIOSYSTEMS, INC.
INDUCEMENT AWARD PLAN
STOCK OPTION GRANT NOTICE
T2 Biosystems, Inc., a Delaware corporation, (the “Company”), pursuant to its Inducement Award Plan, as amended from time to time (the “Plan”), hereby grants to the holder listed below (“Participant”), an option to purchase the number of shares of Common Stock (“Stock”) set forth below (the “Option”). The Option is subject to the terms and conditions set forth in this Stock Option Grant Notice (the “Grant Notice”) and the Stock Option Agreement attached hereto as Exhibit A (the “Agreement”) and the Plan, which are incorporated herein by reference. Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in the Grant Notice and the Agreement.
Participant: |
|
Grant Date: |
|
Exercise Price per Share: | $ |
Total Exercise Price: | $ |
Total Number of Shares Subject to the Option: | shares |
Expiration Date: |
|
Vesting Commencement Date: |
|
Vesting Schedule: | [To be specified in individual agreements] |
Type of Option: | Non-Qualified Stock Option |
By Participant’s signature below, Participant agrees to be bound by the terms and conditions of the Plan, the Agreement and the Grant Notice. Participant has reviewed the Agreement, the Plan and the Grant Notice in their entirety, has had an opportunity to obtain the advice of counsel prior to executing the Grant Notice and fully understands all provisions of the Grant Notice, the Agreement and the Plan. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan, the Grant Notice or the Agreement.
T2 BIOSYSTEMS, inc. | PARTICIPANT
| ||
By: |
| By: |
|
Print Name: |
| Print Name: |
|
Title: |
|
|
|
|US-DOCS\98701315.2||
EXHIBIT A
TO STOCK OPTION GRANT NOTICE
STOCK OPTION AGREEMENT
Pursuant to the Grant Notice to which this Agreement is attached, the Company has granted to Participant an Option under the Plan to purchase the number of shares of Stock set forth in the Grant Notice.
GENERAL
GRANT OF OPTION
|US-DOCS\98671751.3||
PERIOD OF EXERCISABILITY
As used in this Agreement, “Cause” shall mean (a) the Board’s determination that Participant failed to substantially perform Participant’s duties (other than any such failure resulting from Participant’s disability); (b) the Board’s determination that Participant failed to carry out, or comply with any lawful and reasonable directive of the Board or Participant’s immediate supervisor; (c) Participant’s conviction, plea of no contest, plea of nolo contendere, or imposition of unadjudicated probation for any felony, indictable offense or crime involving moral turpitude; (d) Participant’s unlawful use (including being under the influence) or possession of illegal drugs on the premises of the Company or any of its Subsidiaries or while performing Participant’s duties and responsibilities; or (e) Participant’s commission of an act of fraud, embezzlement,
|US-DOCS\98701315.2||
misappropriation, misconduct, or breach of fiduciary duty against the Company of any of its Subsidiaries. Notwithstanding the foregoing, if Participant is a party to a written employment or consulting agreement with the Company (or its Subsidiary) in which the term “cause” is defined, then “Cause” shall be as such term is defined in the applicable written employment or consulting agreement.
|US-DOCS\98701315.2||
EXERCISE OF OPTION
|US-DOCS\98701315.2||
Notwithstanding any of the foregoing, the Administrator shall have the right to specify all conditions of the manner of exercise, which conditions may vary by country and which may be subject to change from time to time.
|US-DOCS\98701315.2||
OTHER PROVISIONS
|US-DOCS\98701315.2||
|US-DOCS\98701315.2||
|US-DOCS\98701315.2||
* * * * *
|US-DOCS\98701315.2||
T2 Biosystems, inc.
InDUCEMENT AWARD plan
RESTRICTED STOCK GRANT NOTICE
T2 Biosystems, Inc., a Delaware corporation (the “Company”), pursuant to its Inducement Award Plan, as amended from time to time (the “Plan”), hereby grants to the holder listed below (“Participant”) the number of shares of Restricted Stock (the “Shares”) set forth below. The Shares are subject to the terms and conditions set forth in this Restricted Stock Grant Notice (the “Grant Notice”) and the Restricted Stock Agreement attached hereto as Exhibit A (the “Agreement”) and the Plan, which are incorporated herein by reference. Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in the Grant Notice and the Agreement.
Participant: |
|
Grant Date: |
|
Total Number of Shares of Restricted Stock: |
|
Vesting Schedule: | [To be specified in individual agreements] |
By Participant’s signature below, Participant agrees to be bound by the terms and conditions of the Plan, the Agreement and the Grant Notice. Participant has reviewed the Agreement, the Plan and the Grant Notice in their entirety, has had an opportunity to obtain the advice of counsel prior to executing the Grant Notice and fully understands all provisions of the Grant Notice, the Agreement and the Plan. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan, the Grant Notice or the Agreement.
T2 Biosystems, Inc. Holder: | PARTICIPANT
| ||
By: |
| By: |
|
Print Name: |
| Print Name: |
|
Title: |
|
|
|
|
|
|
|
|
|
|
|
A-1
|US-DOCS\98704411.2||
EXHIBIT A
TO RESTRICTED STOCK GRANT NOTICE
RESTRICTED STOCK AGREEMENT
Pursuant to the Grant Notice to which this Agreement is attached, the Company has granted to Participant the number of Shares set forth in the Grant Notice.
GENERAL
ISSUANCE OF SHARES
FORFEITURE AND TRANSFER RESTRICTIONS
|US-DOCS\98704411.2||
The Unreleased Shares shall be held by the Company until such Unreleased Shares are forfeited as provided in Section 3.1, until such Unreleased Shares are fully released from the Forfeiture Restriction as provided in Section 3.2 or until such time as this Agreement is no longer in effect. Participant shall not retain physical custody of any certificates representing Unreleased Shares issued to Participant. Participant, by acceptance of this Award, shall be deemed to appoint, and does so appoint, the Company and each of its authorized representatives as Participant’s attorney(s)-in-fact to effect any transfer of forfeited Unreleased Shares (and Retained Distributions, if any, paid on such forfeited Unreleased Shares) to the Company as may be required pursuant to the Plan or this Agreement, and to execute such representations or other documents or assurances as the Company or such representatives deem necessary or advisable in connection with any such transfer. To the extent allowable by Applicable Law, the Company, or its designee, shall not be liable for any act it may do or omit to do with respect to holding the Shares in escrow and while acting in good faith and in the exercise of its judgment.
The Company will retain custody of all cash dividends and other distributions (“Retained Distributions”) made or declared with respect to Unreleased Shares (and such Retained Distributions will be subject to the Forfeiture Restriction and the other terms and conditions under this Agreement that are applicable to the Shares) until such time, if ever, as the Unreleased Shares with respect to which such Retained Distributions shall have been made, paid or declared shall have become vested pursuant to the Grant Notice. Retained Distributions that were made or declared in cash will be retained by the Company in a bookkeeping account until the Unreleased Shares with respect to which such Retained Distributions relate shall have become vested pursuant to the Grant Notice, at which time the Company shall release to Participant the amount retained in the Participant’s bookkeeping account, without interest, as cash; provided that, at the Company’s option, Retained Distributions may be deemed reinvested in notional shares of Stock such that upon release and distribution of such Retained Distributions to Participant, Participant shall be entitled to receive on the date of such distribution or release an amount of cash or the number of whole shares of Stock or a combination thereof, as determined by the Administrator, the aggregate fair value of
A-2
|US-DOCS\98704411.2||
which shall be equal to the Fair Market Value of the notional shares of Stock to which such released Retained Distributions relate. Any Retained Distributions with respect to Unreleased Shares shall be forfeited in the event such Unreleased Shares are forfeited.
TAXATION AND TAX WITHHOLDING
The Company and its Subsidiaries have the authority to deduct or withhold, or require Participant to remit to the Company or the applicable Subsidiary, an amount sufficient to satisfy applicable federal, state, local and foreign taxes (including the employee portion of any FICA obligation) required by law to be withheld with respect to any taxable event arising pursuant to this Agreement. The Company and its Subsidiaries may withhold or Participant may make such payment in one or more of the forms specified below:
A-3
|US-DOCS\98704411.2||
With respect to any withholding taxes arising in connection with the Shares, in the event Participant fails to provide timely payment of all sums required pursuant to Section 4.3(a), the Company shall have the right and option, but not the obligation, to treat such failure as an election by Participant to satisfy all or any portion of Participant’s required payment obligation pursuant to Section 4.3(a)(ii) or Section 4.3(a)(iii) above, or any combination of the foregoing as the Company may determine to be appropriate. The Company shall not be obligated to deliver any certificate representing the Shares to Participant or his or her legal representative unless and until Participant or his or her legal representative shall have paid or otherwise satisfied in full the amount of all federal, state, local and foreign taxes applicable with respect to the taxable income of Participant resulting from the vesting of the Shares or any other taxable event related to the Shares.
In the event any tax withholding obligation arising in connection with the Shares will be satisfied under Section 4.3(a)(iii), then the Company may elect to instruct any brokerage firm determined acceptable to the Company for such purpose to sell on Participant’s behalf a whole number of shares of Stock from those Shares that are then becoming vested as the Company determines to be appropriate to generate cash proceeds sufficient to satisfy the tax withholding obligation and to remit the proceeds of such sale to the Company or the Subsidiary with respect to which the withholding obligation arises. Participant’s acceptance of this Award constitutes Participant’s instruction and authorization to the Company and such brokerage firm to complete the transactions described in this Section 4.3(c), including the transactions described in the previous sentence, as applicable. The Company may refuse to deliver any certificate representing the Shares to Participant or his or her legal representative until the foregoing tax withholding obligations are satisfied.
Participant is ultimately liable and responsible for all taxes owed in connection with the Shares, regardless of any action the Company or any Subsidiary takes with respect to any tax withholding obligations that arise in connection with the Shares. Neither the Company nor any Subsidiary makes any representation or undertaking regarding the treatment of any tax withholding in connection with the awarding, vesting or payment of the Shares or the subsequent sale of the Shares. The Company and the Subsidiaries do not commit and are under no obligation to structure this Award to reduce or eliminate Participant’s tax liability.
RESTRICTIVE LEGENDS AND STOP-TRANSFER ORDERS
THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO FORFEITURE IN FAVOR OF THE COMPANY AND MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE
A-4
|US-DOCS\98704411.2||
TERMS OF A RESTRICTED STOCK AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY.
OTHER PROVISIONS
A-5
|US-DOCS\98704411.2||
A-6
|US-DOCS\98704411.2||
* * * * *
A-7
|US-DOCS\98704411.2||
T2 Biosystems, INC.
INDUCEMENT AWARD PLAN
RESTRICTED STOCK Unit Grant Notice
T2 Biosystems, Inc., a Delaware corporation (the “Company”), pursuant to its Inducement Award Plan, as amended from time to time (the “Plan”), hereby grants to the holder listed below (“Participant”) the number of Restricted Stock Units (the “RSUs”) set forth below. The RSUs are subject to the terms and conditions set forth in this Restricted Stock Unit Grant Notice (the “Grant Notice”) and the Restricted Stock Unit Agreement attached hereto as Exhibit A (the “Agreement”) and the Plan, which are incorporated herein by reference. Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in the Grant Notice and the Agreement.
Participant: |
|
Grant Date: |
|
Number of RSUs: |
|
Type of Shares Issuable: | Common Stock |
Vesting Schedule: | [To be specified in individual agreements] |
By Participant’s signature below, Participant agrees to be bound by the terms and conditions of the Plan, the Agreement and the Grant Notice. Participant has reviewed the Agreement, the Plan and the Grant Notice in their entirety, has had an opportunity to obtain the advice of counsel prior to executing the Grant Notice and fully understands all provisions of the Grant Notice, the Agreement and the Plan. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan, the Grant Notice or the Agreement.
T2 BIOSYSTEMS, Inc. Holder: | PARTICIPANT | ||
By: |
| By: |
|
Print Name: |
| Print Name: |
|
Title: |
|
|
|
|
|
|
|
|
|
|
|
8
|US-DOCS\98704303.2||
Exhibit A
TO RESTRICTED STOCK UNIT Grant Notice
RESTRICTED STOCK UNIT AGREEMENT
Pursuant to the Grant Notice to which this Agreement is attached, the Company has granted to Participant the number of RSUs set forth in the Grant Notice.
general
award of restricted stock UNITS and DIVIDEND EQUIVALENTS
9
|US-DOCS\98704303.2||
10
|US-DOCS\98704303.2||
11
|US-DOCS\98704303.2||
other provisions
12
|US-DOCS\98704303.2||
13
|US-DOCS\98704303.2||
14
|US-DOCS\98704303.2||
* * * * *
15
|US-DOCS\98704303.2||